Thrombotic Microangiopathy

Thrombotic microangiopathy (TMA) represents a critical medical emergency where delays in diagnosis and management can lead to irreversible organ failure or death. At its core, TMA is defined by a pathologic triad: microvascular thrombosis, microangiopathic hemolytic anemia (MAHA), and thrombocytopenia. Your ability to rapidly distinguish between its major subtypes—thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS)—directly determines the lifesaving treatment you must initiate. Mastering this differentiation is a high-stakes skill in clinical hematology and internal medicine.

Defining the Pathologic Process

Thrombotic microangiopathy is not a single disease but a syndrome characterized by specific vascular injury. The hallmark is the formation of microscopic blood clots (thrombi) within the small arterioles and capillaries. These thrombi are composed primarily of platelets, which explains the consumptive thrombocytopenia (low platelet count). As red blood cells attempt to navigate this obstructed, damaged microvasculature, they are physically sheared apart. This process of intravascular hemolysis produces schistocytes (fragmented RBCs) on the blood smear and leads to microangiopathic hemolytic anemia.

The end-organ damage you see clinically—whether neurological symptoms, renal failure, or cardiac ischemia—stems directly from this widespread microvascular occlusion. The critical question becomes: what is the inciting event that triggers this thrombotic cascade? The answer separates TTP from HUS and dictates your therapeutic approach.

Thrombotic Thrombocytopenic Purpura (TTP): An ADAMTS13 Deficiency

TTP is primarily caused by a severe deficiency in a specific plasma enzyme called ADAMTS13. Its physiological role is to cleave ultralarge multimers of von Willebrand factor (VWF) that are released from endothelial cells. In a state of severe ADAMTS13 deficiency (typically activity <10%), these ultralarge VWF multimers accumulate unabated. They act as hyper-adhesive strings that spontaneously bind and activate platelets, leading to the unchecked platelet clumping that characterizes TTP's microthrombi.

The deficiency is most commonly acquired via autoantibodies that inhibit ADAMTS13 function (immune-mediated TTP). More rarely, it can be congenital due to mutations in the ADAMTS13 gene. Clinically, the classic pentad of TTP includes fever, neurological abnormalities, renal impairment, MAHA, and thrombocytopenia, but relying on the full pentad delays diagnosis. In practice, the combination of MAHA and thrombocytopenia in the absence of another clear cause should immediately raise suspicion for TTP. The neurological symptoms can range from headache and confusion to seizures and coma, reflecting cerebral microvascular ischemia.

Hemolytic Uremic Syndrome (HUS): Complement and Infection

HUS shares the TMA pathology but has different underlying mechanisms, primarily affecting the kidneys. It is categorized into two main forms: typical (diarrhea-positive) and atypical.

Typical HUS is often referred to as Shiga toxin-producing E. coli (STEC)-HUS, most famously associated with the O157:H7 serotype. The Shiga toxin binds to glycolipid receptors on renal endothelial cells, causing direct cellular damage, apoptosis, and a prothrombotic state. The management is primarily supportive—vigorous hydration, management of hypertension and renal failure, and avoidance of antibiotics that may increase toxin release. Plasma exchange is not typically beneficial.

Atypical HUS (aHUS) is complement-mediated. It results from uncontrolled activation of the alternative complement pathway due to genetic mutations in regulatory proteins (e.g., factor H, factor I, membrane cofactor protein) or acquired autoantibodies against factor H. This leads to complement deposition on endothelial surfaces, causing injury and thrombosis. Unlike STEC-HUS, aHUS often has a prodrome of upper respiratory infection and carries a high risk of progression to end-stage renal disease if not treated specifically.

The Diagnostic Pivot: ADAMTS13 Activity

The single most crucial laboratory test in the differential diagnosis of acute TMA is the ADAMTS13 activity assay. This test is the pivot point for therapeutic decision-making.

• A level of <10% is highly diagnostic for TTP, especially if an inhibitor (antibody) is also detected.
• A level of >10% suggests the process is not immune-mediated TTP and should shift your suspicion toward HUS (typical or atypical), other drug-induced TMAs, or secondary causes like malignancy or transplantation.

While awaiting this send-out test, which can take hours to days, you must use clinical and readily available lab clues. The presence of a severe diarrheal prodrome points to STEC-HUS (confirm with stool culture/PCR). Dominant renal failure is more characteristic of HUS, while prominent neurological symptoms favor TTP. However, these overlaps mean you cannot rely on clinical features alone.

Treatment Protocols: From Plasma Exchange to Complement Blockade

Treatment must often begin empirically based on clinical suspicion before confirmatory labs return, given the mortality of untreated TTP approaches 90%.

1. For Suspected TTP: Urgent Plasma Exchange (PLEX). This is the definitive emergency treatment. PLEX serves a dual purpose: it removes the pathogenic autoantibodies against ADAMTS13 and replenishes the missing functional enzyme. Therapy is initiated as 1.0 to 1.5 total plasma volume exchanges daily until the platelet count has normalized for at least two days, followed by a gradual taper. Concurrent immunosuppression with corticosteroids (e.g., prednisone 1 mg/kg/day) is standard to suppress antibody production. The anti-CD20 monoclonal antibody rituximab is increasingly used early in the course to induce a more durable remission by depleting B-cells.

1. For Atypical HUS: Complement Inhibition. The cornerstone of therapy is eculizumab, a monoclonal antibody that binds to complement protein C5, preventing the formation of the membrane attack complex (C5b-9). By blocking terminal complement activation, it halts the endothelial damage driving the disease. Treatment leads to rapid improvement in platelet counts and renal function. Vaccination against Neisseria meningitidis is required prior to starting therapy due to the associated risk of meningococcal infection.

1. For STEC-HUS: Supportive Care. The management is centered on meticulous supportive care: fluid and electrolyte balance, renal replacement therapy if needed, and control of hypertension. Antibiotics and antimotility agents are generally avoided in the diarrheal phase as they may increase the risk of releasing more Shiga toxin.

Common Pitfalls

• Waiting for the Full Clinical Picture: Waiting for the classic pentad (fever, neuro symptoms, renal impairment, MAHA, thrombocytopenia) to manifest in TTP is a fatal error. Initiate the TTP workup and consider emergent PLEX upon finding the duo of MAHA and thrombocytopenia without another explanation.
• Misinterpreting the Coagulation Profile: A common trap is confusing TMA with disseminated intravascular coagulation (DIC). In TMA, the prothrombin time (PT) and activated partial thromboplastin time (aPTT) are typically normal, and fibrinogen is normal or elevated. In DIC, the PT/aPTT are usually prolonged, and fibrinogen is low. Relying on D-dimer is not helpful, as it can be elevated in both conditions.
• Delaying Treatment for Confirmatory Tests: The ADAMTS13 activity result should not delay the initiation of plasma exchange if clinical suspicion for TTP is high. Treat first while confirming the diagnosis.
• Overlooking Secondary Causes: TMA can be secondary to conditions like malignant hypertension, scleroderma renal crisis, certain drugs (e.g., chemotherapy, calcineurin inhibitors), or hematopoietic stem cell transplantation. Treating the underlying condition is paramount alongside TMA-directed therapy.

Summary

• Thrombotic microangiopathy (TMA) is a syndrome defined by microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and microvascular thrombosis causing end-organ ischemia.
• The urgent diagnostic priority is differentiating between thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) using history, presentation, and the pivotal ADAMTS13 activity test.
• TTP is driven by a severe deficiency of ADAMTS13 (<10%) and is a hematologic emergency requiring immediate plasma exchange (PLEX) and immunosuppression.
• HUS has two main forms: Shiga toxin-associated (STEC-HUS), managed supportively, and atypical HUS (aHUS), a complement-mediated disorder treated with the C5 inhibitor eculizumab.
• Rapid diagnosis and subtype-specific treatment are essential to prevent irreversible damage to the brain, kidneys, and other organs from widespread microvascular thrombosis.